Use of new biochemical plasmatic markers, plasma free and total metanephrines, for the diagnosis and follow-up of neuroblastoma in children with clinical correlation by Jobe, Ch.
  
CHUV | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS 
Master’s Thesis 
Use of new biochemical plasmatic markers, plasma free and total 
metanephrines, for the diagnosis and follow-up of neuroblastoma in 
children with clinical correlation 
 
Christophe Jobé 
 
 
 
 
 
Tutors: Eric Grouzmann, Maja Beck Popovic, Thierry Buclin 
 
 
 
Contacts: christophe.jobe@unil.ch, eric.grouzmann@chuv.ch 
 
 
 
 
2012 
 
 
UNIL| Université de lausanne 
 
 
Keywords: Neuroblastoma, Biomarkers, Metanephrine, Monitoring, Diagnostic 
 
 
 
 
  
 Table of contents 
Title .................................................................................................................................................. 0 
Abstract ................................................................................................................................................ 1 
Résumé ................................................................................................................................................. 2 
Introduction .......................................................................................................................................... 4 
Materials and Methods ......................................................................................................................... 5 
Study design and participants .......................................................................................................... 5 
Laboratory analyses ......................................................................................................................... 5 
Graphics and statistical analysis ...................................................................................................... 5 
Results .................................................................................................................................................. 6 
Comparison of the biomarkers at diagnosis ..................................................................................... 6 
Variation of biomarkers in the population ................................................................................................ 6 
Diagnostic performance ............................................................................................................................ 7 
Comparison between the gold standard and plasmatic values for the monitoring of the disease in 
patients ............................................................................................................................................. 9 
Results of the ordinal logistic regression ................................................................................................. 11 
Discussion .......................................................................................................................................... 16 
Bibliography....................................................................................................................................... 17 
Figures and Tables .............................................................................................................................. 19 
Appendices ......................................................................................................................................... 25 
 
 
  
 Abstract 
 
 
Background: 
 
Neuroblastoma is a paediatric tumour derived from the neural crest. Biochemical diagnosis 
and follow up rely on quantitation of urinary catecholamines (dopamine and noradrenaline) 
and their metabolites vanillylmandelic acid (VMA) and homovanillic acid (HVA) (gold-
standard). When combined, these analyses have a sensitivity of 95%. However, they are 
clearly limited by inaccuracy of urine collection in young children and normalisation of 
catecholamine concentrations by creatininuria. Recent development in biochemical 
diagnosis of pheochromocytoma, another neural crest tumour found in adults, shows that 
plasmatic measurement of methoxylated catecholamines called metanephrines are more 
sensitive and specific than other biomarkers. Moreover, a study to determine the reference 
intervals for metanephrines in a pediatric population has recently been completed. The aim 
of this work is to describe the role of metanephrines monitoring in the follow up of 
neuroblastoma.  
 
Method: 
 
This retrospective study included patients with neuroblastoma in whom the following 
parameters were determined: plasma free and total metanephrines, plasma 
catecholamines, 24h urinary catecholamines and metanephrines in absolute value and 
corrected by creatinine, VMA and HVA at the diagnosis and during treatment at the 
University Hospital of Lausanne (Switzerland). Eleven patients aged between the first day 
of life and 7 years old were followed between 2005 and 2012. Clinical outcome and 
biochemical concentrations of the analytes were correlated. 
 
Results: 
 
At diagnosis, plasma free and total normetanephrines and methoxytyramine have a 
sensitivity of 100% compared to 85% for the actual gold standard. Metanephrine remain 
below the upper reference limit as expected since these tumours do not produce 
adrenaline.  
The relationship between biochemical markers and clinical outcome is illustrated 
graphically. Plasma or urinary normetanephrine and methoxytyramine correlate better with 
the history of the patient than VMA and HVA, as evaluated by ordinal logistic regression.  
Concentrations of analytes in urine show a better correlation with clinical events when the 
results are corrected by creatininuria. 
 
Conclusion: 
 
Normetanephrine and methoxytyramine reflect disease history in neuroblastoma patients 
and could play a significant role in the follow up of this type of tumour. Formal studies in a 
sufficient number of patients are needed to confirm this preliminary observation. 
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Résumé 
 
 
Introduction: 
 
Le neuroblastome est une tumeur de l’enfant dérivant de la crête neurale. Le diagnostic 
biochimique et le suivi sont basés sur les dosages des catécholamines urinaires 
(dopamine et noradrénaline) et de leurs métabolites acides vanillylmandélique (VMA) et 
l’acide homovanillique (HVA) (analyses diagnostiques de référence). Ensemble, ils ont une 
sensibilité de 95%, mais l'inconvénient de cette technique est une collection incertaine des 
urines de 24 h ou bien d’un spot urinaire pour lequel les concentrations doivent être 
normalisées par la créatinine. De récents développements dans le domaine du diagnostic 
biochimique du phéochromocytome, une autre tumeur neuroendocrinienne observée 
principalement chez les adultes, montrent que le dosage plasmatique des catécholamines 
méthoxylées appelées métanéphrines est plus sensible et spécifique que les autres 
biomarqueurs. Une étude visant à déterminer les limites de référence pour ces paramètres 
dans une population pédiatrique a déjà été effectuée. Le but de ce travail est de décrire le 
rôle de la mesure des métanéphrines dans le suivi des neuroblastomes. 
 
Méthode: 
 
Cette étude rétrospective inclue des patients avec un neuroblastome chez lesquels les 
métanéphrines plasmatiques libres et totales, les catécholamines plasmatiques, les 
catécholamines et métanéphrines urinaires de 24h et normalisées par la créatinine ont été 
mesurées pour le diagnostic et le suivi clinique à l’hôpital universitaire de Lausanne 
(Suisse). Onze patients âgés du premier jour de vie à 7 ans ont été suivis entre 2005 et 
2012. 
 
Résultats: 
 
Au moment du diagnostic, la normétanéphrine et la métoxytyramine plasmatique libre et 
totale ont une sensibilité de 100% contre 85% pour les dosages urinaires (méthode 
diagnostique de référence). Les concentrations d’analytes dérivant de l’adrénaline reste 
en-dessous la limite supérieure de la norme étant donné que ces tumeurs ne produisent 
pas d’adrénaline mais de la noradrénaline. 
La relation entre les concentrations des marqueurs biochimiques et l’évolution clinique de 
ces patients a été étudiée graphiquement. La normétanéphrine et la méthoxytyramine 
plasmatique et urinaire décrivent mieux l'histoire du patient que l'acide vanillylmandélique 
et l’acide homovanillique, selon une analyse par régression logistique ordinale. La 
normétanéphrine et la methoxytyramine urinaires ont une meilleure performance quand 
elles sont corrigées par la créatininurie. 
 
Conclusion: 
 
La normétanéphrine et méthoxytyramine reflètent l'histoire clinique des patients atteints 
d’un neuroblastome et pourraient assurément jouer un rôle dans le suivi clinique de ces 
tumeurs. Une étude de plus grande envergure sur un plus grand nombre de patients 
devrait être réalisée afin de confirmer ces observations préliminaires.  
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 Introduction 
 
Neuroblastoma is the most common extra-cranial solid tumor in children and originates 
from the sympathetic nervous system. It shows a wide variety of biological activity and has 
a correspondingly diverse range of presenting features and prognosis. Patients below 18 
months of age usually have a better outcome than older ones and require less intensive 
treatment, and indeed some children may not require any treatment at all, since the 
tumour can spontaneously regress. In contrast, older children often present with more 
advanced and biologically aggressive forms of the disease and the outcome is often poor 
despite very intensive treatment1. The primary sites are in the retroperitoneum 
(approximately 65% of the cases), posterior mediastinum (approximately 20%), pelvis (< 
5%), and neck (<5%); sometimes, no primary site is identiﬁed. In 50% to 60% of the 
patients, the metastases are found in the cortical bone, bone marrow, lymph nodes, and/or 
liver, but they rarely spread to lung parenchyma or the CNS2.  
As for the clinical presentation, the symptoms are not specific (decline in general health, 
loss of appetite, fever, loss of weight, abdominal pain or, one out of two times, simply the 
detection of a mass at the first exam)3. The diagnosis is made by histological analysis of 
biopsy and elevated urinary catecholamines (noradrenaline and dopamine) and their acid 
metabolites: vanillylmandelic acid (VMA) and homovanillic acid (HVA). According to 
Candito4, these measurements are considered to be the gold standard for diagnosis and 
follow-up. Metabolism of the catecholamines and their metabolites is depicted in figure 1. 
According to Hartmann's study, 88% of the neuroblastoma are secreting one of the 3 
urinary metabolites (HVA, VMA and dopamine) whereas the remaining tumors are 
metabolically inactive5.    
A more recent study established that combined urine catecholamines and their metabolites 
(VMA and HVA) have a very good sensitivity (95%)6 . However, 24h-urine samples may 
not always be collected reliably, especially in neonates and paediatric patients. Therefore, 
a study from Pussard et al. in 2008 has determined reference values for age-dependent 
variations of creatinine and was thus able to take measurements on random untimed urine 
specimens by correcting them with urinary output of creatinine excretion7.  
In adults, a recent study evaluated plasma free and total metanephrines as diagnostic tool 
in pheochromocytoma8 (another tumor derived from the neural crest) and showed that 
they were as sensitive and specific as urinary fractionated metanephrines. Thus, their 
value and role could be of interest in pediatric neuroblastoma.  
A first study was carried out to establish reference values of free and total 
normetanephrines (NMN), free and total metanephrine (MN) and free and total 
methoxytyramine (MT) in healthy children and to compare with measurements in a few 
patients with neuroblastoma9. Based on these reference values, we reviewed 11 patients 
with neuroblastoma with the aim to compare laboratory values with clinical data at 
diagnosis and during treatment, and thus to describe the role of metanephrines monitoring 
in the follow up of neuroblastoma. 
 
 
  
 
 
 
4 
 Materials and Methods 
 
Study design and participants 
 
This retrospective study included patients with neuroblastoma in whom plasma free and 
total metanephrines, plasma catecholamines, 24h urinary catecholamines and 
metanephrines and urinary catecholamines and metanephrines correlated with creatinine 
as well as VMA and HVA were measured for the diagnosis and during monitoring of the 
disease at the University Hospital of Lausanne (Switzerland). Eleven patients aged 
between the first day of life and 7 years were followed between 2005 and 2012.  
All measurements were performed at the Laboratory of Clinical Pharmacology and 
Toxicology in Lausanne.  
 
Clinical data are summarized in Table 1.  
 
Laboratory analyses 
 
Laboratory analyses are following the same methodology previously published10.  
Blood sampling. All blood samples were collected by puncture with the patient kept 
seated for at least 20 min before sampling. Patients were instructed to fast and to abstain 
from chocolate beverages or bananas or acetaminophen overnight. All samples were 
collected onto ice and centrifuged within 30 min after puncture. Plasma was kept at −80 °C 
until analysis. Twenty-four-hour urinary metanephrines and catecholamines were collected 
into opaque bottles containing hydrochloric acid to ensure analyte stability.  
Analyses.The plasma samples were analyzed by HPLC with coulometric detection for 
total metanephrines after acid hydrolysis 11 and plasma free metanephrines were 
quantified by tandem mass spectrometry12. Metanephrines in urine were analyzed by 
HPLC as total hydrolysis-fractionated normetanephrine and metanephrine 13. Plasma 
catecholamines (norepinephrine and epinephrine) were analyzed using HPLC with 
amperometric detection  14 Catecholamines, VMA and HVA were determined by HPLC with 
amperometric detection (reference III)."Reference values for plasma analyses were 
determined in a paediatric patient population in our institution after receiving the 
agreement from the ethical committee of the CHUV (figure 3). Reference values for urine 
parameters are shown in figure 4-5 (8). 
 
Graphics and statistical analysis 
 
The graphical analysis of the biomarker values are represented as the percentage over the 
upper reference limit normalized to the age of the patient. The established limits of 
reference values such as used by the laboratory of the CHUV in Lausanne are shown in 
table 2-4.   
The various markers at diagnosis are expressed as absolute value and as ratio over their 
upper reference limit. Specificity of the biomarkers during the disease monitoring could not 
be determined as every patient had the disease. We focused on the following markers: the 
actual gold standard used at the CHUV (U NE, U DA, U VMA, U HVA) and the O-
methylated lines (MN, NMN and MT in the plasma free (PF), total (PT) and urine (U) lines).  
For monitoring of the disease, the laboratory values are expressed as ratio over their 
5 
 upper reference limit and are compared according to RECIST score (complete remission 
(CR) partial remission (PR), progressive disease (PD)) and response of the treatment 
(chemotherapy and surgery). 
 
Statistical analysis for the follow up allowed comparing the performances of the different 
biomarkers available with regard to clinical evolution and treatment response. Clinical 
outcomes were coded as RECIST scores (1-4), considered as ordinal variable, while the 
biomarkers were expressed first as log-transformed absolute laboratory values and, in a 
second step, as log-transformed ratios of percentage of the upper reference normalized for 
age of the patient. A model of ordinal logistic regression, which still included the repetition 
of tests within each patient, was finally applied to relate each biomarker to the outcome 
along follow up time. 
We used for this intent an "ordered logit" model. We began by exploring whether time itself 
had an effect. The longitudinal formulation of this model takes into consideration 
intrapatient correlation. We omitted the diagnosis period (RECIST=0, which trivially occurs 
in early follow up). 
We explored all biomarkers with the same model to compare their respective performance 
for outcome prediction.  
Statistical analyses were performed using STATA (v10, Statacorp, College Station, TX, 
USA). 
 
 
 
Results  
 
Comparison of the biomarkers at diagnosis 
 
Variation of biomarkers in the population 
 
Eleven patients (patient 1-11) diagnosed with neuroblastoma were analysed. Their age 
was (mean ± SD) 1.13 ± 1.60 years. Twenty-two different biomarkers were measured for 
diagnosis, Plasma free MN, NMN and MT were measured in patient 3 to 11. Total plasma 
MN, NMN and MT were measured in all patients. 24h urinary E, NE, DA, HVA and VMA 
were measured in patient 1, 3, 4, 5, 6, 7, 10, 11. 24h urinary NE were measured in patient 
1, 3, 4, 5, 7, 11. 24H urinary MN, NMN, MT were measured in patient 1, 3, 4, 6, 7, 10, 11. 
Urinary E, NE, DA normalized to the creatinine were measured in patient 1, 2, 3, 4, 6, 7, 8, 
9, 11. Urinary NE normalized to the creatinine was measured in patient 1, 2, 3, 4, 7, 8, 9, 
11. Urinary MN, NMN, MT normalized to the creatinine were measured in patient 1, 2, 3, 4, 
6, 7, 8, 11. Urinary HVA and VMA normalized to the creatinine were measured in patient 1, 
2, 3, 6, 7, 8, 9, 11.  
 
 
 
The most abnormal values reflecting a diagnostic potential are presented in Figure 2. It 
appeared that the parameters that are the most above their URL are fNMN, tNMN, fMT 
and tMT. VMA and HVA were also above their respective URL but with less amplitude. U 
NE, U DA and U NMN were disappointing since 2 patients were detected as negatives.  
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Figure 2: Catecholamines and derivatives express as fraction of the upper reference limit 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The statistics analysis of the adrenergic line’s biomarkers is shown in table 5-6. According 
to the literature, neuroblastoma does not produce the adrenergic line excepted for the 
VMA who derives from the noradrenergic line, too. Similarly, we found the same with our 
patients since the median of the adrenergic line ranged between 22% for U E and 105% 
for 24h U MN, but there is just one value very high (patient 6: 5950. %) with the rest of the 
medians not higher than 68% (U MN). These results were arbitrary used as the baseline of 
the physiological catecholamine production. For every biomarker there is always at least 
one patient upper the URL. Strikingly, the fNMN or tNMN are more than 2000% of the 
upper reference limit. 
Noradrenergic line data are shown in the table 7-8. fNMN (1st quartile 702%, median 
1022%) and tNMN (1st quartile 546%, median 677%) have a better sensitivity (100%) than 
U NE( 50%) and U VMA (87%). The U NE has a median of 89% of the URL.  
Dopaminergic line data are shown in table 9-10. fMT (1st quartile 447%, median 596%) 
and tMT (1st quartile 179%, median 220%) have a better sensitivity (100%) than U D 
sensitivity (55%) and U HVA sensitivity (87%). 
U NE (median 89%) and U DA (median 166%) provide a sensitivity of 50% and 55%. The 
combination of U VMA and U HVA gave a sensitivity of 100% but two patients (2 and 8) 
have just one of each marker below the reference limit when adjusted to the creatininuria.  
The combination of the noradrenergic and the dopaminergic line provided the best 
sensitivity indicating that neuroblastoma preferentially produced these metabolites. In this 
study, fNMN and fMT have both 100% of sensitivity, the same for tNMN and tMT. But the 
median of plasma free line concentrations is higher than the median of plasma total line. 
24h U VMA (1st quartile 314%, median 387%) and HVA (1st quartile 204%, median 235%) 
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 have a combined sensitivity of 100%. 
 
Normalized ratio of adrenergic 
line 
Adrenergic Line 
F P MN T P MN 24h U E 
24h U 
MN 
U E U MN 
24h U 
VMA 
U VMA 
Mean 0.4 0.7 0.4 9.3 0.4 0.9 4.0 7.2 
Max 1.5 2.4 1.0 59.5 1.7 1.7 7.2 20.1 
Min 0.1 0.1 0.1 0.3 0.0 0.4 1.3 0.8 
Standard deviation 0.4 0.8 0.4 22.2 0.5 0.4 1.9 6.9 
Quartile(25 centile) 0.3 0.2 0.2 0.6 0.2 0.6 3.1 2.2 
Median 0.3 0.3 0.3 1.1 0.2 0.7 3.9 4.3 
Quartile(75 centile) 0.4 0.8 0.6 1.4 0.4 1.1 4.8 10.3 
Sensibility 0.1 0.3 - 0.6 0.1 0.4 1.0 0.9 
Table 5: statistics with the adrenergic line at diagnosis, the values are expressed as a ratio over their 
upper reference limit. 
 
 Adrenergic Line 
F P MN T P MN 24h U E 24h U 
MN 
U E U MN 24h U 
VMA 
U VMA 
mean 0.16 5.27 7.00 1'445.86 18.89 324.13 58.25 96.25 
max 0.59 20.86 17.00 8'926.00 75.00 836.00 101.00 281.00 
min 0.07 0.92 1.00 52.00 1.00 96.00 18.00 11.00 
standard deviation 0.17 6.68 6.28 3'299.52 24.38 272.24 25.69 100.07 
median 0.11 2.28 3.50 220.00 8.00 217.00 61.50 52.00 
Table 6: statistics are done with the direct laboratory values 
 
Normalized ratio of 
noradrenergic line 
Noradrenergic Line 
F P 
NMN 
T P 
NMN 
24h U 
NE 
24h U 
NMN 
U NE U NMN 
24h U 
VMA 
U VMA 
mean 37.8 86.7 2.3 75.8 1.6 52.0 4.0 7.2 
max 165.5 694.6 6.1 421.2 4.5 306.5 7.2 20.1 
min 5.1 1.6 0.4 0.6 0.2 1.0 1.3 0.8 
standard deviation 57.7 206.7 2.3 154.6 1.6 105.8 1.9 6.9 
quartile(25 centile) 7.0 5.5 0.6 6.7 0.3 4.6 3.1 2.2 
median 10.2 6.8 1.4 7.9 0.9 7.5 3.9 4.3 
quartile(75 centile) 19.7 30.8 3.3 43.9 3.0 25.5 4.8 10.3 
sensibility 1.0 1.0 0.7 0.9 0.5 0.9 1.0 0.9 
Table 7: statistics with the noradrenergic line at diagnosis, the values are expressed as a ratio over 
their upper reference limit. 
 
 
Noradrenergic Line 
F P 
NMN 
T P 
NMN 
24h U 
NE 
24h U 
NMN 
U NE U NMN 
24h U 
VMA 
U VMA 
mean 39.02 930.87 200.50 41'689.14 309.13 135'648.50 58.25 96.25 
max 175.41 7'432.00 607.00 227'471.00 857.00 837'429.00 101.00 281.00 
min 3.16 20.60 23.00 317.00 31.00 1'144.00 18.00 11.00 
standard deviation 61.82 2'210.84 215.26 83'109.70 350.19 292'227.51 25.69 100.07 
median 9.34 85.55 148.00 5'901.00 136.50 5'125.50 61.50 52.00 
Table 8: statistics are done with the direct laboratory values 
 
Normalized ratio of 
dopaminergic line 
Dopaminergic Line 
F P MT T P MT 
24h U 
DP 
24h U 
MT 
U DP U MT 
24h U 
HVA 
U HVA 
mean 15.4 10.1 2.7 4.5 2.2 3.4 2.5 2.6 
max 55.7 65.2 10.0 12.3 6.3 6.2 3.6 5.9 
min 1.5 1.3 0.1 0.6 0.3 0.8 1.8 0.7 
standard deviation 20.9 19.4 3.4 4.5 2.2 2.3 0.7 1.8 
quartile(25 centile) 4.5 1.8 0.8 1.1 0.9 1.4 2.0 1.5 
median 6.0 2.2 1.3 2.0 1.7 3.2 2.4 1.9 
quartile(75 centile) 8.4 4.4 2.8 7.1 1.9 5.3 2.8 3.8 
sensibility 1.0 1.0 0.6 0.7 0.6 0.8 1.0 0.9 
Table 9: statistics with the noradrenergic line at diagnosis, the values are expressed as a ratio over 
their upper reference limit 
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Dopaminergic Line 
F P MT T P MT 24h U DP 
24h U 
MT 
U DP U MT 
24h U 
HVA 
U HVA 
mean 1.19 69.15 2'944.13 2'278.00 2'247.33 3'392.13 43.25 50.75 
max 4.45 425.78 12'042.00 4'784.00 4'688.00 9'284.00 70.00 118.00 
min 0.11 12.37 49.00 774.00 395.00 1'214.00 28.00 14.00 
standard deviation 1.69 125.35 4'241.32 1'352.79 1'464.56 3'196.30 14.02 37.51 
median 0.42 19.78 999.50 2'094.00 2'495.00 1'849.50 39.00 34.50 
Table 10: statistics are done with the direct laboratory values 
 
 
Comparison between the gold standard and metanephrines for the 
monitoring of the disease in patients  
 
 
Clinical history and monitoring of the disease of patients are shown in the following graphs 
in figures 3-10. Patients are classified by final RECIST score: progressive disease (PD), 
partial remission (PR), complete remission (CR). For each patient, 4 graphs are done with 
different biomarkers: 
- Gold standard: NE, DA, HVA, VMA, panel A 
- Plasma total MN, NMN, MT, panel B 
- Plasma free MN, NMN, MT, panel C 
- Urinary MN, NMN, MT, panel D 
We followed the variation of each biomarker in correlation with therapeutic interventions 
and RECIST score for each patient. 
- During the progressive disease, we expect an elevation of the biomarker upper the 
URL. 
- During the partial remission, we expect to detect a difference between the other 
periods. 
- During the remission, we expect the biomarkers stay under the URL. 
 
PD patients: 
Patient 3: 
The diagnosis was made at 40 months of life. A Chemotherapeutic protocol was 
immediately initiated. No decrease of the size of the tumour was noticed after receiving 2 
different cures while after the surgical resection, he was in complete remission, but still 
received radiotherapy as adjuncted treatment. Less than one year later, he had a 
recurrence of metastasis, had a last cure of chemotherapy which had a short effect. Two 
and half years after the onset of the disease, he died. 
The 4 graphs depicted on figure 3 showed that the markers also had the same tendency to 
fail after the first cure of chemotherapy. For the first recurrence, only the fNMN shows an 
increase over the URL. All analytes showed an increased concentration during the second 
recurrence but plasma free line has the most impressive rise being upper 10 times above 
the range (panel C),better than DA (highest value for the gold standard) which has a value 
2.5 times above the range. 
Patient 8: 
The diagnosis was made the first day of life, two months later he received his first 
chemotherapy. But a half year after, the primary tumour and the metastases progressed. 
9 
 He received 4 more chemotherapy cycles and had a surgery before he was in complete 
remission. Two years later, MIBG detected an infiltration of the bone marrow. We stopped 
the study at this time.  
The 4 graphs depicted on figure 4 showed that during the first recurrence tNMN, HVA and 
VMA values were 10 times above the range (panel A and B). During the complete 
remission, all analytes have a tendency to fall; plasma total line stays borderline around 
the URL after the first recurrence (panel B). The second recurrence is only revealed with 
fMT (panel C), plasma total line has a tendency to elevate his values (panel B), but the 
gold standard stays below its URL (panel A). 
 
PR patients: 
Patient 5: 
The diagnosis was done at 7 months of life, one month later, he began a chemotherapy. 
After that, he was in partial remission since the primary mass was still detected by the 
MRI.  
All lines, depicted on figure 5 fall after the diagnosis and all stay borderline within the URL 
during the partial remission. 
Patient 11: 
The diagnosis was done at 4 years and 9 months of life. A first chemotherapy treatment 
followed by surgery resulted in partial remission.  6 months later, he received another 
chemotherapy cure. His last MIBG still showed few captation of the primary tumour and 
metastases (already present at diagnosis).  
All lines, depicted on figure 6 gradually decreased after the first chemotherapy and stay 
below the range during the partial remission, except for fMT (panel A) and HVA (panel C) 
that were above their URL. 
 
CR patients: 
Patient 4: 
The diagnosis was done at 10 months of life. The patient received one cycle of 
chemotherapy and after 3 months of disease was in complete remission and remains as it 
after 5 years (the longest follow up of this study). 
All graphs depicted on figure 7 showed a quick fall of all biomarkers after the 
chemotherapy. During the complete remission, the gold standard (panel A) and the U line 
(panel D) stay under the range. Plasma free (panel C) and plasma total (panel B) lines 
stay borderline and occasionally cross the upper reference limit. All analytes overlap their 
concentrations with the adrenaline line known to not be involved in neuroblastoma 
biochemistry. 
Patient 6: 
The diagnosis was made at 1 month of life. He directly received chemotherapy and after 6 
months, he was in complete remission.  
The 4 graphs depicted on figure 8 showed that all analytes sharply decreased after 
chemotherapy and remain below their URL 
Patient 7: 
The diagnosis was made at 22 months of life. He directly received one chemotherapy cure 
and after 5 months had a laminectomy. 5 months later he had a complete resection of the 
primary mass. 
The 4 graphs depicted on figure 9 showed that all analytes sharply decreased after 
chemotherapy and remain below their URL 
Patient 10: 
The diagnosis was made the first day of life. He directly had a surgery followed by 2 cures 
of chemotherapy and was in complete remission.  
Unfortunately, we don’t have any urinary values at diagnosis (depicted on figure 10, panel 
10 
 A and D). Of note, plasma free and total lines were 100-700 times above the range. The 4 
graphs during the complete remission showed that all analytes sharply decreased after 
chemotherapy and remain below their URL  
Results of the ordinal logistic regression 
 
Time itself after diagnosis time seems to increase the probability of aggravation but to a 
statistically non-significant extent (p = 0.16). The results of the ordinal logistic regression 
analysis performed on each time series of biomarker values are shown in table 11, which 
gives the odds ratio associated with one log increase in the marker value along with the 
corresponding statistical significance p.value.  According to this analysis, the best 
biomarker for the noradrenergic metabolic line is the urinary NMN (p=0,001) and the best 
biomarker for the dopaminergic line is the F MT (p=0,012). 
 
Line Adrenergic Noradrenergic Dopaminergic 
 val.abs. ratio 
norm. 
val.abs. ratio 
norm. 
val.abs. ratio 
norm. 
P F . . 1.59  
p=0.07 
1.62 
p=0.07 
1.64  
p=0.08 
1.86 
p=0.012 
P T . . . . 2.13  
p=0.06 
2.54 
p=0.02 
24h U 
Catecholamines 
. 0.47 
p=0.03 
. . 3.30  
p=0.08 
3.34 
p=0.10 
U Catecholamines 0.44 
p=0.07 
. . . . 6.43 
p=0.02 
24h U Metanephrine . . 3.84 
p=0.001 
2.83 
p=0.004 
3.60 
p=0.011 
. 
U Metanephrine . . 2.16 
p=0.008 
5.24 
p=0.001 
3.21 
p=0.005 
3.61 
p=0.013 
24h U acid (NA) 2.62 
p=0.02 
2.23 
p=0.04 
3.33 
p=0.008 
2.78 
p=0.03 
U acid 1.80 
p=0.08 
2.31 
p=0.03 
2.34 
p=0.05 
3.57 
p=0.005 
Table 11: Statistical results 
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Figure 3-10: Monitoring of patient 3, 4, 5, 6, 7, 8, 10, 11 by U NE, U DA, U HVA, U VMA for the gold standard 
and MN, NMN and MT in P F, P T and U, expresses as fraction of the upper reference limit. RECIST score and 
treatment. 
 
 
Discussion 
 
This is the first study reporting longitudinal profiles of plasma free and total metanephrine 
concentrations in neuroblastoma paediatric patients in relation with clinical outcome. Since 
the size of the population investigated is small, we stay descriptive and have made few 
statistics that indicated some trends favouring plasma metanephrines monitoring to follow 
up the patients. 
 
At diagnosis 
 
According to the literature15, HVA and VMA concentrations normalized by creatinine 
present a good sensitivity of 95% at the diagnosis. With our small group of patients, we 
find a sensitivity of 100% for this combination, but 18% of our patients just have a positive 
value with VMA or HVA. However, the urinary values are clearly limited by inaccuracy of 
urine collection in young children and normalisation of concentrations by creatininuria. To 
overcome this problem, plasma sampling appears more confident and indeed, at 
diagnosis, plasma free NMN and MT or plasma total NMN and MT are over the upper 
reference limit for each patient providing 100 % of sensitivity. Plasma free line has higher 
values at diagnosis than plasma total line in comparison to their respective upper 
reference limit.  
The use of urinary catecholamines (NE and DA) for diagnosis is disappointing since we 
observed a sensitivity of 50% and 55%, respectively. 
A prospective randomised study including more patients should confirm these preliminary 
observations.   
 
Monitoring of the disease 
 
Plasma free line seems to represent the best the clinical history. It shows every 
recurrence, metanephrines concentrations fall after a treatment and is the only line which 
detects a difference between a complete remission and a partial remission. Plasma total 
NMN + MT and urinary NMN + MT adjusted to the creatinine show the same trend but, 
during the complete remission, the urinary line seems to have less variation.   
HVA and VMA of the gold standard are good biomarkers for the diagnosis, although less 
clearly than the plasma line. However, VMA and HVA have less sensitivity during the follow 
up of the patients most probably because they are a metabolic endpoint of catecholamine 
Diagnostic time Complete Remission Partial Remission Stable disease 
Progressive disease Chemotherapy/Radiotherapy Surgery 
Urinary NE (creat) Urinary DA (creat) Urinary HVA (creat) 
MN MT 
Urinary VMA (creat) 
NMN 
16 
 produced by the tumors but also deriving from the diet. Nevertheless, all markers don’t 
show every recurrence and we can’t differentiate a complete of a partial remission based 
on biochemical measurements. 
 
As predicted from the literature5, we found that plasma free and total MN stay under the 
upper reference limit during all period investigated since neuroblastoma did not produce 
adrenaline.  
We encountered some difficulties during this study. The first one was to validate the 
RECIST for each value. RECIST criteria are made for adult oncology and not children, this 
was described in McHugh’s papers16,17. The second one was to select criteria to analyse. 
There are a lot of different markers and there aren’t enough studies about the monitoring 
to make any proposition of guide lines according to a systematic review of molecular and 
biological tumor markers in neuroblastoma18. The third one was to analyse the laboratory 
values expressed as a ratio over their URL. The URL of the F P and T P are not yet 
finalized and the paper still in preparation. The forth one was to combined two biomarkers 
because of the production of noradrenergic and dopaminergic catecholamine in 
neuroblastoma.  
 
 
Conclusion: 
 
Normetanephrine and methoxytyramine are clearly associated to disease history in 
neuroblastoma patients, with a good sensitivity and specificity at the time of diagnosis, and 
a significant association with clinical evolution during follow up.  
 
Formal studies in a larger number of patients are needed to confirm this preliminary 
observation and to precisely assess the role of these biomarkers in the post-treatment 
monitoring of these patients.  
. 
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 Figures and Tables 
 
 
 
 
 
 
 
Figure 1: Metabolism of catecholamine, the minor metabolites, dihydroxymandelic acid (DHMA) and 
dihydroxyphenylethanol (DOPET), are not shown. AD, aldehyde dehydrogenase; AR, aldehyde 
reductase; NMN, normetanephrine; SAM, S-adenosyl methionine. 
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 Abbreviations list 
fMN Plasma free metanephrine tMN Plasma total metanephrine 
fNMN  Plasma free normetanephrine tNMN  Plasma total normetanephrine 
fMT Plasma free methoxytyramine tMT Plasma total methoxytyramine 
E Epinephrine DA Dopamine 
NE Norepinephrine   
HVA Homovanillic acid VMA Vanillylmandelic acid 
24h U  24h urinary U Urinary adapted to creatinine 
CR Complete Response PR Partial Response 
SD Stable Disease PD Progressive Disease 
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 Table 1: 
 
pt nb age at dg (m) stage histology MYCN other treatment outcome 
1 0 4S FH - - no CR 
2 10 4 FH - 1pdel no PD 
3 40 4 - - - CT, RT, S PD 
4 10 4 IH - - CT CR 
5 7 4s FH - - CT PR 
6 1 3 - - - CT CR 
7 22 3 FH - - CT, S CR 
8 0 4s - - - CT, S PD 
9 0 4s FH - - S CR 
10 0 4s - - - CT, S CR 
11 57 3 UF - - CT, S PR 
 
m: months 
CT: chemotherapy 
RT: radiotherapy 
S: surgery 
FH: favourable histology (according to Shimada) 
IH: intermediate histology 
UH: unfavourable histology 
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 Table 2: Upper reference limit determined by CHUV’s laboratory1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma
MN NMN MT MN NMN MT
0-1 an <0.39 <1.06 <0.08 <8.68 <10.7 <6.53
1-2 ans <0.61 <0.96 <0.1 <6.74 <8.94 <6.66
2-3 ans <0.39 <0.46 <0.03 <4.44 <5.68 <4.84
3-5 ans <0.26 <0.45 <0.05 <6.64 <9.86 <11.68
5-8 ans <0.35 <0.76 <0.03 <5.14 <10.14 <4.86
Free (nmol/l) Total (nmol/l)
22 
 Table 3: Upper reference limit used by CHUV’s laboratory for VMA and HVA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
23 
 Table 4 : Upper reference limit used by CHUV’s laboratory for urinary catecholamined and 
O-methylated urinary line 
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